Pharma Journalist 9038 posts 0 comments

Zymeworks Inc. announced that it and longtime partner, Merck (known as MSD outside the US and Canada) have signed a new license agreement granting Merck the right to develop additional…
Read More...

Ridgeback Biotherapeutics announces the start of enrollment in a Phase 2 trial of potential COVID-19 treatment EIDD-2801. The new trial will be conducted using the new COVID-19 drug…
Read More...

Moderna, Inc., announced that it has completed enrollment for both cohorts of the Phase 2 study of its vaccine candidate (mRNA-1273) against COVID-19. mRNA-1273 is Moderna’s second mRNA…
Read More...

Xencor, Inc. and Atreca, Inc. announced that the companies have entered into a collaboration and license agreement to research, develop and commercialize T cell engaging bispecific…
Read More...

Concert Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the Company’s oral Janus kinase inhibitor, CTP-543,…
Read More...

AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that LYNPARZA has been approved in the European Union (EU) as a monotherapy for the maintenance…
Read More...

Corvus Pharmaceuticals, Inc. announced that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19. The first cohort of five patients…
Read More...

Turning Point Therapeutics, Inc. and Zai Lab announced an exclusive license agreement for the development and commercialization of Turning Point’s lead drug candidate, repotrectinib, in…
Read More...

The European Investment Bank (EIB) and CureVac, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimised mRNA, entered into a €75…
Read More...

Novavax, Inc. announced that it has been selected to participate in Operation Warp Speed (OWS), a U.S. government program that aims to begin delivering millions of doses of a safe,…
Read More...